



GENE EXPRESS APPOINTS DAVID LESTER SENIOR VICE PRESIDENT OF STRATEGY AND CORPORATE DEVELOPMENT

Toledo, OH - October 2, 2007 – Gene Express, Inc. today announced the appointment of David S. Lester, Ph.D. to Senior Vice President of Strategy and Corporate Development.

Gerald Vardzel, CEO of Gene Express, commented, “Dr. Lester brings over 14 years of pharmaceutical research and clinical development expertise, including leading research and development efforts, as well as managing the process from both the corporate and regulatory perspectives. His extensive knowledge of the FDA process, experience in biomarkers and enhanced clinical trial design and reputation in the industry will be valuable assets as we execute our strategy. He has been an outspoken and prominent contributor in the personalized medicine and biomarker and diagnostic industries.”

Prior to joining Gene Express, Dr. Lester spent several years at Pfizer in the Global Research and Development Group and in the Global Pharmaceutical Group. During his tenure with Pfizer, Dr. Lester held several key positions including head of the New York site for Global Clinical Technology; Founder and Director of Pfizer Human Health Technologies; and Director of Clinical Technology for New Product Development. Previously, Dr. Lester established, and was Director of Clinical Technologies for Experimental Medicine at Pharmacia. He is also the Founder and President of ITHW, Inc., a consultancy group focusing on innovative technologies in health and wellness.

In addition, Dr. Lester spent a total of seven years at the FDA serving as Senior Science Advisor to the Office of Pharmaceutical Sciences, Acting Associate Director of Interdisciplinary Science to the Office of Testing and Research, and Team Leader for the Neural and Cellular Pharmacology Group in the Division of Applied Pharmacologic Research. His academic career includes some of the world’s best research facilities such as the NIH, the Weizmann Institute of Science, the Max Planck Institute of Biophysical Chemistry and Harvard University Medical School. Dr. Lester is often invited to speak at national and international symposiums and serves on numerous conference advisory boards. Dr. Lester has published over 60 refereed scientific publications, has edited five volumes, and has contributed to numerous book chapters and reviews. Previously, he was also active in advocating science policy, including authoring a number of significant publications.

Dr. Lester stated, “I am very excited to be joining such a strong team at Gene Express. Gene Express’s StaRT-PCR™ technology will set the standards for use of PCR in molecular diagnostics by providing quantitative and quality controlled gene expression data, with the potential to enhance development of both drugs and diagnostics. This is a crucial element in the

successful implementation of personalized medicine. I look forward to playing an integral role in the Company's promising future growth."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's \$3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at www.geneexpressinc.com.

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact:

Rachel Levine
The Global Consulting Group
Tel: 646-284-9439
E: rlevine@hfgcg.com